Rocket Pharmaceuticals
RCKT
58 hedge funds and large institutions have $142M invested in Rocket Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 10 closing their positions.
600% more call options, than puts
Call options by funds: $7K | Put options by funds: $1K
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
3% less funds holding
Funds holding: 60 → 58 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
35% less capital invested
Capital invested by funds: $218M → $142M (-$76.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$7.25M |
| 2 |
SAM
Senzar Asset Management
New York
|
+$3.29M |
| 3 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$1.14M |
| 4 |
FO
FT Options
Chicago,
Illinois
|
+$1.07M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$646K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIM
RS Investment Management
San Francisco,
California
|
-$18M |
| 2 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$3.86M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$1.46M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.09M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$825K |
RCKT Hedge Fund Activity: Q1 2016 in Review
58 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q1 2016, worth a combined $142M — down 35% from $218M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of RCKT and 8 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 26 added.
The largest buyer was OrbiMed, adding an estimated $7.25M. The largest seller was RS Investment Management, exiting entirely with an estimated $18M sold.
- 58 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q1 2016, down from 60 in Q4 2015.
- Funds reported $142M of Rocket Pharmaceuticals stock for Q1 2016, down 35% quarter-over-quarter.
- 8 funds opened new Rocket Pharmaceuticals positions in Q1 2016 and 10 closed out, a net change of -2 holders.
- The largest Rocket Pharmaceuticals buyer in Q1 2016 was OrbiMed, an estimated $7.25M added.
- The largest Rocket Pharmaceuticals seller in Q1 2016 was RS Investment Management, an estimated $18M sold.
Based on aggregated 13F filings for Q1 2016.